Metabolic syndrome remission after Roux-en-Y gastric bypass or sleeve gastrectomy

Bariatric surgery is known to decrease weight and the prevalence of comorbidities, but there is little evidence on the differential effect of Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) on the remission of the aggregate outcome, metabolic syndrome, 4 years after surgery. The purpose...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes, metabolic syndrome and obesity metabolic syndrome and obesity, 2017-01, Vol.10, p.393-402
Main Authors: Nassour, Ibrahim, Almandoz, Jaime P, Adams-Huet, Beverley, Kukreja, Sachin, Puzziferri, Nancy
Format: Article
Language:English
Subjects:
Bariatric surgery
Body mass index
Care and treatment
Cholesterol
Diabetes
Females
Gastrectomy
Gastrointestinal surgery
Hyperlipidemia
Hypertension
Internal medicine
Laparoscopy
Medical records
Metabolic syndrome
Metabolic syndrome X
Mortality
Obesity
Original Research
Patients
Remission (Medicine)
Risk assessment
Risk factors
Surgeons
Surgical outcomes
Weight control
weight loss
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bariatric surgery is known to decrease weight and the prevalence of comorbidities, but there is little evidence on the differential effect of Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) on the remission of the aggregate outcome, metabolic syndrome, 4 years after surgery. The purpose of this study was to determine the effectiveness of RYGB and SG on metabolic syndrome in veterans. We retrospectively reviewed consecutive patients who underwent SG and RYGB at the Dallas Veterans Affairs Medical Center from 2003 to 2012. We determined the effect of both the operations on the remission of metabolic syndrome, its individual components, and medium-term morbidity and mortality. A sensitivity analysis was performed using propensity matching. A total of 266 patients were identified (159 RYGB and 107 SG) with 96% follow-up after 4 years. The mean age of the cohort was 51.4 years; the majority of patients were male (59%) and Caucasian (69%). RYGB patients had a greater mean body mass index and were more likely to have hypertension or hypertriglyceridemia. RYGB was associated with a similar metabolic syndrome remission to SG (37.6% vs 26.8%; =0.09). The percentage of weight loss was 26.5% after RYGB and 10.8% after SG at 4 years post operation (
ISSN:1178-7007
1178-7007
DOI:10.2147/DMSO.S142731